VEGFA and metabolic dysfunction-associated steatotic liver disease: NAFLD patients often exhibit elevated levels of coagulation factors FVIII, FIX, FXI, and FXII in their bloodstream, along with increased levels of fibrinogen, von Willebrand factor, and plasminogen activator inhibitor-1, and reduced levels of antithrombin III and protein C. They may also experience altered blood concentrations of vascular endothelial growth factor (VEGF) that affect atherogenesis and plaque instability.